I really hate to advise anyone on the stock market.
But
I really hate to advise anyone on the stock market.
But If you believe in this company and have the balls and patience to wait for things to develop then anywhere you come in at this level would be ok since the upside is so good here, IF everything we believe now is true about the patent and if we get partners then anywhere in this range will be in very early on this stock. With that said you may see this bleed down more. Like i said no crystal ball here. But the upside makes this range cheap in the long run. I wish you all the best and all this is my opinion only.
NaturalShrimp Inc. (SHMP) Stock Research Links
Everything is IMO and I do not advise selling or buying.
Your own DD will do that.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Transcosmos Achieves Recognition at Contact Center Awards Recognized for clear, goal-oriented strategy working together with clients. TOKYO /PRNewswire/ -- transcosmos is thrilled to share that the company has been awarded the Special Jury Award in the Strategy category at the Contact Center Awards 2025. This prestigious event is sponsored by the Editorial Office of...
Continue Reading
HCW Biologics Collaborates with WY Biotech on a Licensing Agreement HCW Biologics has taken an exciting step forward by entering into a license agreement with WY Biotech for a transformative preclinical immunotherapeutic product candidate. This partnership positions both companies to harness innovative technologies in the biopharmaceutical landscape. Financial Aspects of...
Continue Reading
The Buzz Behind Bucked Up®'s Limited-Edition Flavor You know, there's caffeine, and then there's Bucked Up®'s caffeine kick—it’s a whole different animal. But now they’ve spiced things up a notch with their new Hunt: Orange Cream flavor. It’s plastered on every product from their line, from Bucked Up® to the wacky-named Woke AF®. Feels like they’re saying,...
Continue Reading
The Impressive Growth of SPS Commerce SPS Commerce (NASDAQ: SPSC) has carved out a strong position in the market, consistently providing remarkable returns. Over the last 15 years, this company has outpaced average market growth by a staggering 13.26% each year, resulting in an average annual return of 25.11%. As of now, SPS Commerce enjoys a robust market capitalization...
Continue Reading
Innovating Genomic Sequencing for Newborns QIAGEN (NYSE: QGEN) is making significant strides in the field of genomic medicine by partnering with Genomics England on a remarkable initiative aimed at sequencing the genomes of newborns. This pioneering effort seeks to screen for over 200 genetic conditions, facilitating early diagnosis and intervention for rare health...
Continue Reading